Lenalidomide monotherapy for necrobiotic xanthogranuloma
Authors:
Open Access
- 3 June 2026
- journal article
- case report
- Published by Elsevier in JAAD Case Reports
- Vol. 74, 126-128
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Low Dose Pegylated Interferon Alpha as a First‐Line Treatment for Necrobiotic XanthogranulomaJEADV Clinical Practice, 2025
- Periorbital necrobiotic xanthogranuloma resolved with three years of systemic lenalidomide treatmentAmerican Journal of Ophthalmology Case Reports, 2024
- Systemic therapy of necrobiotic xanthogranuloma: a systematic reviewOrphanet Journal of Rare Diseases, 2022
- A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic CriteriaJAMA Dermatology, 2020
- Necrobiotic xanthogranuloma: a 30-year single-center experienceAnnals of Hematology, 2018
- Complete Response to Thalidomide and Dexamethasone in a Patient With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathy: A Case Report and Review of the LiteratureClinical Lymphoma Myeloma and Leukemia, 2011
- Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide.2010
- Mechanism of action of lenalidomide in hematological malignanciesJournal of Hematology & Oncology, 2009
- Efficacy of Lenalidomide in Myelodysplastic SyndromesNew England Journal of Medicine, 2005
- [Necrobiotic xanthogranuloma in paraproteinemia].1989